Early clinical trials suggest that these more specialized immune checkpoints namely LAG-3 in combination with PD-1 blockade exhibit a superior safety profile compared with PD-1 plus CTLA-4 blockade with equivocal anti-tumor activity (Figure 1) (52). This evidence concerns the gene CTLA4 and neoplasm.